ABUSArbutus Biopharma Corp
Arbutus Biopharma Corp (ABUS) is a biopharmaceutical company focused on the development and commercialization of RNA-based therapeutics, including lipid nanoparticle (LNP) delivery systems. The next catalyst is November 16, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain its rapid revenue growth and deliver on its capital return strategy.
- Revenue surged 128.2% YoY to $191.41M in 2026, driven by licensing and litigation settlements.
- Net income reached $326.50M, with a net margin of 170.6%, reflecting strong licensing revenue and cost control.
- Free cash flow remains negative at -$86.43M (TTM), but the company has $76.58M in shareholders’ equity and a debt-to-equity ratio of 0.00x.
The Read
Arbutus Biopharma’s final procedural catalysts, including patent litigation verdicts and oral hearings, have historically triggered median absolute stock moves of about 5%.
The schedule
- Mon16Nov
The earnings release will test whether the company can deliver a positive surprise on revenue and guidance, following a recent earnings miss that raised concerns about cash runway.
- Thu31Dec
The investor FAQ will test the market's reaction to management's outlook on clinical progress and patent litigation outcomes, which could influence investor sentiment ahead of the next earnings report.
- Sat20Feb
This earnings report will test the company's ability to deliver a strong revenue and guidance reset, following the previous quarter's mixed results. The focus will be on cash flow and clinical trial progress.
- Sun2May
The investor day will provide a platform for management to outline strategic priorities, including clinical and patent updates, which could influence the stock's direction ahead of the next earnings report.
- Sat22May
This earnings report will test the company's ability to deliver a strong revenue and guidance reset, with a focus on clinical progress and cash flow. The outcome will be critical for assessing the company's long-term viability.
- Mon9Aug
The earnings release will test whether the company can deliver a positive surprise on revenue and guidance, with a focus on clinical trial progress and patent litigation outcomes.
- Tue24Aug
The events and presentations will provide insight into the company's strategic priorities, including clinical and patent updates, which could influence investor sentiment ahead of the next earnings report.
Past
- Wed12Aug
Actual outcome: Bull · $4.71 at outcome
Arbutus reported in-line earnings with no surprises, but the stock rallied due to the announcement of a $230 million share repurchase program, which signaled management's confidence in the stock's value. The price action reflected positive sentiment around the strategic capital allocation move, which supported the bull case.
Q2 2026 earnings will be the first full print following the $950 million upfront Moderna settlement. Focus shifts entirely to strategic capital allocation and whether management will pursue accelerated R&D or shareholder returns.
- Tue30Jun
Actual outcome: Bull · $5.04 at outcome
The Unified Patent Court issued a favorable final ruling that upheld the validity of Arbutus's LNP patents across key European jurisdictions. This significant legal victory solidified the company's intellectual property moat and strengthened its leverage for future licensing or settlements, driving the stock to hold near the bull target.
A final procedural decision from the Unified Patent Court (UPC) following the May 1st oral hearing regarding the validity of Arbutus’s LNP patents in European jurisdictions.
- Fri1May
Actual outcome: Mixed · $4.44 at outcome
The UPC oral hearing resulted in a non-committal procedural update rather than a definitive ruling on the validity of Arbutus’s LNP patents, leaving the strength of their European IP position unresolved. The stock remained flat at $4.32 because the lack of a clear 'win' or 'loss' prevented a re-rating of long-term royalty optionality while also avoiding the downside risk of a patent invalidation.
The UPC oral hearing resulted in a non-committal procedural update rather than a definitive ruling on the validity of Arbutus’s LNP patents, leaving the strength of their European IP position unresolved. The stock remained flat at $4.32 because the lack of a clear 'win' or 'loss' prevented a re-rating of long-term royalty optionality while also avoiding the downside risk of a patent invalidation.
- Thu26Mar
Actual outcome: Bull · $4.29 at outcome
Arbutus met earnings expectations with an EPS of -$0.04 and reported a strong financial position with $91.5 million in cash and marketable securities. While the stock initially dipped around the earnings release, the confirmation of a solid cash runway alleviated concerns over R&D burn rates, ultimately driving the stock past the $4.35 bull target in the following weeks.
Arbutus met earnings expectations with an EPS of -$0.04 and reported a strong financial position with $91.5 million in cash and marketable securities. While the stock initially dipped around the earnings release, the confirmation of a solid cash runway alleviated concerns over R&D burn rates, ultimately driving the stock past the $4.35 bull target in the following weeks.
- Sun1Mar
Actual outcome: Bear · $4.48 at outcome
Arbutus and Genevant announced a global patent settlement with Moderna, securing a $950 million upfront payment and an additional $1.3 billion contingent on the resolution of Moderna's Section 1498 appeal. Despite the historic settlement size, the stock fell 4.1% by the outcome date, as the market likely viewed the upfront cash as already priced in and discounted the delayed, contingent nature of the remaining payout.
Arbutus and Genevant announced a global patent settlement with Moderna, securing a $950 million upfront payment and an additional $1.3 billion contingent on the resolution of Moderna's Section 1498 appeal. Despite the historic settlement size, the stock fell 4.1% by the outcome date, as the market likely viewed the upfront cash as already priced in and discounted the delayed, contingent nature of the remaining payout.
